Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

86.41
Delayed Data
As of Jul 22
 -1.38 / -1.57%
Today’s Change
55.00
Today|||52-Week Range
133.62
-20.32%
Year-to-Date
3 Stocks Dragging In The Drugs Industry
Jul 22 / TheStreet.com - Paid Partner Content
Is Agenus or Ariad Pharmaceuticals the Better Long-Term Buy?
Jul 19 / MotleyFool.com - Paid Partner Content
Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain?
Jul 21 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close87.79
Today’s open88.47
Day’s range86.37 - 88.99
Volume642,725
Average volume (3 months)1,225,804
Market cap$16.2B
Dividend yield--
Data as of 3:59pm ET, 07/22/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-37.50%
Earnings growth (next 5 years)+118.55%
Revenue growth (last year)+47.36%
P/E ratio332.3
Price/Sales26.95
Price/Book94.23

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.22+0.24%
PRGOPerrigo Company PLC+0.94+1.03%
MDVNMedivation Inc+0.09+0.14%
VRTXVertex Pharmaceutica...+0.68+0.73%
Data as of 4:02pm ET, 07/22/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.00
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts

Partner Offers

Search for Jobs